6. Commitments and Contingencies (Details Narrative) (USD $)
|
3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Mar. 31, 2014
|
|
Potential severance under certain employment agreements | $ 1,130,000us-gaap_SeveranceCosts1 | ||||
Aggregated annual salaries under certain employment agreements | 935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent | 935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent | |||
Product revenue | 2,651,000us-gaap_SalesRevenueGoodsNet | 2,450,000us-gaap_SalesRevenueGoodsNet | 8,142,000us-gaap_SalesRevenueGoodsNet | 8,627,000us-gaap_SalesRevenueGoodsNet | |
Product licensing fees | 378,000us-gaap_LicensesRevenue | 629,000us-gaap_LicensesRevenue | 1,130,000us-gaap_LicensesRevenue | 1,459,000us-gaap_LicensesRevenue | |
Vetericyn and Innovacyn [Member] | |||||
Product revenue |
122,000us-gaap_SalesRevenueGoodsNet / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
652,000us-gaap_SalesRevenueGoodsNet / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
1,110,000us-gaap_SalesRevenueGoodsNet / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
2,682,000us-gaap_SalesRevenueGoodsNet / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
|
Accounts receivable |
28,000us-gaap_AccountsReceivableGross / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
28,000us-gaap_AccountsReceivableGross / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
220,000us-gaap_AccountsReceivableGross / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
||
More Pharma [Member] | |||||
Accounts receivable |
609,000us-gaap_AccountsReceivableGross / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
609,000us-gaap_AccountsReceivableGross / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
790,000us-gaap_AccountsReceivableGross / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
||
Transaction costs |
28,000us-gaap_RelatedPartyTransactionAmountsOfTransaction / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
28,000us-gaap_RelatedPartyTransactionAmountsOfTransaction / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
48,000us-gaap_RelatedPartyTransactionAmountsOfTransaction / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
48,000us-gaap_RelatedPartyTransactionAmountsOfTransaction / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
|
Amortization of upfront fees (transaction costs) |
$ 378,000us-gaap_AmortizationOfDeferredCharges / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
$ 379,000us-gaap_AmortizationOfDeferredCharges / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
$ 1,130,000us-gaap_AmortizationOfDeferredCharges / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
$ 1,131,000us-gaap_AmortizationOfDeferredCharges / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
X | ||||||||||
- Definition
For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The amount of amortization of deferred charges applied against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of transactions with related party during the financial reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|